share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股變動聲明-董事 Borgeson Blake
美股sec公告 ·  07/03 16:41
Moomoo AI 已提取核心訊息
Blake Borgeson, a reporting person at Recursion Pharmaceuticals, Inc. [RXRX], completed a transaction involving the grant of 1,441 shares of Class A Common Stock on July 1, 2024. The shares were acquired at no cost, indicating this was likely an award or grant. Following this transaction, Borgeson's direct holdings in the company amount to a total of 7,178,557 shares of Common Stock.
Blake Borgeson, a reporting person at Recursion Pharmaceuticals, Inc. [RXRX], completed a transaction involving the grant of 1,441 shares of Class A Common Stock on July 1, 2024. The shares were acquired at no cost, indicating this was likely an award or grant. Following this transaction, Borgeson's direct holdings in the company amount to a total of 7,178,557 shares of Common Stock.
Recursion Pharmaceuticals, Inc. [RXRX]的報告人Blake Borgeson於2024年7月1日完成了一項交易，涉及授予1441股A類普通股。股份是免費獲取的，這表明很可能是獎勵或授予。此次交易後，Borgeson在該公司的直接持股總數爲7178557股普通股。
Recursion Pharmaceuticals, Inc. [RXRX]的報告人Blake Borgeson於2024年7月1日完成了一項交易，涉及授予1441股A類普通股。股份是免費獲取的，這表明很可能是獎勵或授予。此次交易後，Borgeson在該公司的直接持股總數爲7178557股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息